WI GOP legislature rejects marijuana amendments; CA ending cannabis testing for prison guards; Researchers slam Schedule I restrictions

Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day.

Your support makes Marijuana Moment possible…

Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there.Support our work at https://www.patreon.com/marijuanamoment/ TOP THINGS TO KNOWThe Wisconsin Senate and Assembly rejected amendments to restore marijuana legalization provisions in the budget that were included by Gov. Tony Evers (D) but stripped out by the legislature’s Republican majority.The California Senate Budget and Fiscal Review Committee approved a bill to ratify a labor agreement ending random drug tests for marijuana among most correctional officers in the state’s prison system.A Department of Defense contractor is suing the federal government, claiming that questions about past marijuana use during a security clearance process violated his Fifth Amendment right against self-incrimination.Federally funded scientists argue in a new journal article that marijuana’s Schedule I status “traps researchers in a paradox” because “proving medical value requires studies, yet studies are heavily restricted” due to ongoing prohibition.Former New York Office of Cannabis Management Official Damian Fagon argues in a new Marijuana Moment op-ed that a recent cannabis poll from a “Big Tobacco”-backed group is “a thinly veiled attempt to persuade policymakers to take a broadly popular issue in a less popular direction.”/ FEDERALThe Drug Enforcement Administration published a list of chemical preparations that it has determined are exempt from certain provisions of the Controlled Substances Act.Rep. Dan Crenshw (R-TX) tweeted about Health and Human Services Secretary Robert F. Kennedy Jr.’s commitment to advancing psychedelics therapy research, saying, “This is the kind of urgency we need. I passed a law in 2022 to fund the first federal trials into psychedelic therapies because too many of my teammates never made it home in one piece. Veteran suicide is a national crisis and this could be a breakthrough. Really appreciate @SecKennedy building on that momentum.”/ STATESFormer Vermont Gov. Peter Shumlin (D) is joining the board of directors of FLUENT Corp.A Pennsylvania senator tweeted, “I’ve introduced SB 49 to create the PA Cannabis Control Board, bringing consistent oversight to medical marijuana & setting safety standards for unregulated hemp products. Time for transparency & stronger protections for all Pennsylvanians.”Rhode Island regulators asked the U.S. Court of Appeals for the First Circuit to uphold the dismissal of a lawsuit challenging the state’s marijuana rules.Maryland regulators adopted changes to rules for the cannabis social equity partnership grant program.Missouri regulators launched a marijuana product sampling and testing initiative.California regulators sent guidance on the form that cannabis products must be in for compliance testing.Minnesota regulators posted guidance about transitioning between hemp and marijuana product regulatory frameworks.Michigan regulators published updated disciplinary guidelines for marijuana businesses.Kentucky regulators published guidance on the medical cannabis card application process.Colorado regulators published a bulletin on when to report psychedelic adverse events.—
Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—
/ INTERNATIONALThe UK Food Standards Agency published updated guidance about CBD products./ SCIENCE & HEALTHA review concluded that “synthetic cannabinoid agonists display significant potential in targeting CB1 and CB2 receptors to inhibit tumor proliferation and promote apoptosis across various cancer types.”A review concluded that “compared to conventional treatments, psychedelics offer faster onset, durable effects, and possible disease-modifying properties, making them promising candidates for future neurotherapeutics.”/ BUSINESSAYR Wellness Inc. announced it did not make an interest payment due on June 30  in connection with outstanding senior notes.Washington, D.C. dispensaries sold $5.8 million worth of medical cannabis in May./ CULTUREMike Tyson discussed his use of cannabis.

Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox.